NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Illinois
This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Henry Gosebruch (“Executive” and, together with the Company, the “Parties”) this June 2, 2023 (the “Effective Date”).
NEUMORA THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • August 9th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CONSULTING AGREEMENT (“Agreement”) is entered into effective as of May 20, 2023 (the “Effective Date”) by and between NEUMORA THERAPEUTICS, INC. (“Neumora” or the “Company”), and John Dunlop (“Consultant”). Neumora desires to retain Consultant as an independent contractor to perform consulting services for Neumora, and Consultant is willing to perform such services, on the terms described below.
NEUMORA THERAPEUTICS, INC. EXECUTIVE CHAIRMAN AGREEMENTExecutive Chairman Agreement • August 9th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE CHAIRMAN AGREEMENT (this “Agreement”) is made and entered into effective as of July 3, 2023 (the “Effective Date”), by and between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul L. Berns, an individual (the “Chairman”).
SEPARATION AGREEMENTSeparation Agreement • August 9th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Separation Agreement (the “Agreement”) by and between John Dunlop (“Executive”), and Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement, which, for the avoidance of doubt, shall not be prior to the Termination Date (as defined below), if not revoked in accordance with Section 5(c)(iii) (the “Effective Date”) with reference to the following facts:
